{{Drugbox
| Watchedfields = changed
| verifiedrevid = 477242623
| IUPAC_name = 1-(8-Chloro-6-phenyl-4''H''-[1,2,4]triazolo[4,5-a][1,4]benzodiazepin-1-yl)-''N'',''N''-dimethylmethanamine
| image = Adinazolam.svg
| width = 180
| image2 = Adinazolam3d.png
| width2 = 150

<!--Clinical data-->
| tradename =  
| pregnancy_category =
| legal_CA = Schedule IV
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =
| metabolism = [[Liver|Hepatic]]
| elimination_half-life = < 3 hours
| excretion = [[Kidney|Renal]]

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 37115-32-5
| ATC_prefix = N05
| ATC_suffix = BA07
| PubChem = 37632
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00546
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 34519
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = KN08449444
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02770
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 251412
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 328250

<!--Chemical data-->
| C=19 | H=18
| Cl=1 | N=5
| molecular_weight = 351.8
| smiles = Clc3cc2\C(=N/Cc1nnc(n1c2cc3)CN(C)C)c4ccccc4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H18ClN5/c1-24(2)12-18-23-22-17-11-21-19(13-6-4-3-5-7-13)15-10-14(20)8-9-16(15)25(17)18/h3-10H,11-12H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = GJSLOMWRLALDCT-UHFFFAOYSA-N
}}

'''Adinazolam'''<ref name = "FR">FR Patent 2248050</ref> (marketed under the brand name '''Deracyn''') is a [[benzodiazepine]] derivative, and more specifically, a [[triazolobenzodiazepine]] (TBZD). It possesses [[anxiolytic]],<ref>{{cite journal | url=http://onlinelibrary.wiley.com/doi/10.1111/j.2042-7158.1998.tb06859.x/abstract | title=Kinetic Characterization and Identification of the Enzymes Responsible for the Hepatic Biotransformation of Adinazolam and N-Desmethyladinazolam in Man |author1=Karthik Venkatakrishnan |author2=Lisa L. Von Moltke |author3=Su Xiang Duan |author4=Joseph C. Fleishaker |author5=Richard I. Shader |author6=David J. Greenblat | journal=Journal of Pharmacy and Pharmacology | date=March 1998 | volume=50 | issue=3 | pages=265–274 | doi=10.1111/j.2042-7158.1998.tb06859.x | pmid=9600717}}</ref> [[anticonvulsant]], [[sedative]], and [[antidepressant]]<ref>{{cite journal | url=http://journals.lww.com/psychopharmacology/Abstract/1987/06000/Adinazolam_A_New_Antidepressant__Findings_of_a.10.aspx | title=Adinazolam-A New Antidepressant: Findings of a Placebo-Controlled, Double-Blind Study in Outpatients with Major Depression. |vauthors=Dunner D, Myers J, Khan A, Avery D, Ishiki D, Pyke R | journal=Journal of Clinical Psychopharmacology | date=June 1998 | volume=7 | issue=3 | pages=170–172 | pmid=3298327}}</ref><ref name=antidepressant>{{cite journal | first = Robert A. | last = Lahti |author2=Vimala H. Sethy|author3=Craig Barsuhn|author4=Jackson B. Hester |date=November 1983 | title = Pharmacological profile of the antidepressant adinazolam, a triazolobenzodiazepine. | journal = Neuropharmacology | volume = 22 | issue = 11 | pages = 1277–82 | pmid = 6320036 | doi = 10.1016/0028-3908(83)90200-9 }}</ref> properties. Adinazolam was developed by Dr. Jackson B. Hester, who was seeking to enhance the antidepressant properties of [[alprazolam]], which he also developed.<ref name=Jackson_B_Hester>{{cite web|url=http://international.phrma.org/publications/publications//admin/2004-10-12.1086.pdf |title=Discovers Award 2004 |accessdate=August 18, 2006 |date=April 2004 |format=PDF |work=Special Publications |publisher=Pharmaceutical Research and Manufacturers of America |pages=39 |archiveurl=https://web.archive.org/web/20060824202348/http://international.phrma.org/publications/publications/admin/2004-10-12.1086.pdf |archivedate=August 24, 2006 |deadurl=no |df= }}</ref> Adinazolam was never FDA approved and never made available to the public market, however it has been sold as a [[designer drug]].<ref>{{cite journal|first1=Bjoern|last1=Moosmann|first2=Philippe|last2=Bisel|first3=Florian|last3=Franz|first4=Laura M.|last4=Huppertz|title=Characterization and ''in vitro'' phase I microsomal metabolism of designer benzodiazepines – an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam, and nitrazolam|url=http://onlinelibrary.wiley.com/doi/10.1002/jms.3840/abstract|journal=Journal of Mass Spectrometry|date=2016|issn=1096-9888|volume=51|issue=|pages=1080–1089|via=Wiley Online Library|doi=10.1002/jms.3840|pmid=27535017|first5=Volker|last5=Auwärter}}</ref>

==Side effects==
Overdose may include [[muscle weakness]], [[ataxia]], [[dysarthria]] and particularly in children paradoxical excitement, as well as diminished reflexes, [[Mental confusion|confusion]] and coma may ensue in more severe cases.<ref>{{cite web | url=http://www.drugbank.ca/drugs/DB00546 | title=Adinazolam | publisher=DrugBank}}</ref>

A human study comparing the subjective effects and abuse potential of adinazolam (30&nbsp;mg and 50&nbsp;mg) with [[diazepam]], [[lorazepam]] and a placebo showed that adinazolam causes the most "mental and physical sedation" and the greatest "mental unpleasantness".<ref>{{cite web | url=https://archives.drugabuse.gov/pdf/monographs/81.pdf | title=The Abuse Potential of Adinazolam: A Comparison with Diazepam, Lorazepam and Placebo | publisher=NIDA Research Monograph No. 81 | date=1987 |author1=M. Bird |author2=D. Katz |author3=M. Orzack |author4=L. Friedman |author5=E. Dessain |author6=B. Beake |author7=J. McEachern |author8=J. Cole }}</ref>

==Pharmacodynamics and pharmacokinetics==
Adinazolam binds to peripheral-type benzodiazepine receptors that interact allosterically with GABA receptors as an [[agonist]] to produce inhibitory effects.

==Metabolism==
Adinazolam was reported to have active metabolites in the August 1984 issue of ''The Journal of Pharmacy and Pharmacology''.<ref name=active_metabolites>{{cite journal | first = Vimala H. | last = Sethy |author2=R. J. Collins|author3=E. G. Daniels |date=August 1984 | title = Determination of biological activity of adinazolam and its metabolites. | journal = Journal of Pharmacy and Pharmacology | volume = 36 | issue = 8 | pages = 546–8 | pmid = 6148400 | doi = 10.1111/j.2042-7158.1984.tb04449.x }}</ref> The main metabolite is ''N''-desmethyladinazolam.<ref name=Peng_1984>{{cite journal | first = G. W. | last = Peng |date=August 1984 | title = Assay of adinazolam in plasma by liquid chromatography | journal = Journal of Pharmaceutical Sciences | volume = 73 | issue = 8 | pages = 1173–5 | pmid = 6491930 | doi = 10.1002/jps.2600730840 }}</ref> NDMAD has an approximately 25-fold high affinity for benzodiazepine receptors as compared to its precursor, accounting for the benzodiazepine-like effects after oral administration.<ref name = "FR" /> Multiple ''N''-dealkylations lead to the removal dimethyl-aminoethyl side chain, leading to the difference in its potency.<ref name = Peng_1984 /> The other two metabolites are alpha-hydroxyalprazolam and [[estazolam]].<ref name=other_metabolites>{{cite journal | first = A. D. | last = Fraser |author2=A. F. Isner|author3=W. Bryan |date=November–December 1993 | title = Urinary screening for adinazolam and its major metabolites by the Emit d.a.u. and FPIA benzodiazepine assays with confirmation by HPLC | journal = Journal of Analytical Toxicology | volume = 17 | issue = 7 | pages = 427–31 | pmid = 8309217 | doi=10.1093/jat/17.7.427}}</ref> In the August 1986 issue of that same journal, Sethy, Francis and Day reported that [[proadifen]] inhibited the formation of N-desmethyladinazolam.<ref name=Sethy_Francis_Day_1986>{{cite journal | first = Vimala H. | last = Sethy |author2=Jonathan W. Francis|author3=J. S. Day |date=August 1986 | title = The effect of proadifen on the metabolism of adinazolam | journal = Journal of Pharmacy and Pharmacology | volume = 38 | issue = 8 | pages = 631–2 | pmid = 2876087 | doi = 10.1111/j.2042-7158.1986.tb03099.x }}</ref>

==See also==
* [[Benzodiazepine]]
* [[Alprazolam]]

==References==
{{Reflist|2}}

{{Anxiolytics}}
{{Benzodiazepines}}
{{GABAAR PAMs}}

[[Category:Benzodiazepines]]
[[Category:Chloroarenes]]
[[Category:Designer drugs]]
[[Category:GABAA receptor positive allosteric modulators]]
[[Category:Hypnotics]]
[[Category:Triazolobenzodiazepines]]